| 716 |
Cisplatin
|
-
Cisplatin, CAS-RN: 15663-27-1, DTXSID4024983
|
472: DNA adduct formation leading to kidney failure
|
| 385 |
Nisoldipine
|
-
Nisoldipine, CAS-RN: 63675-72-9, DTXSID0023371
|
261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility
|
| 387 |
Nitrendipine
|
-
Nitrendipine, CAS-RN: 39562-70-4, DTXSID0023373
|
261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility
|
| 576 |
Etomidate
|
-
Etomidate, CAS-RN: 33125-97-2, DTXSID5023033
|
349: Inhibition of 11β-hydroxylase leading to decresed population trajectory
|
| 389 |
Chloroquine bis(phosphate)
|
-
Chloroquine bis(phosphate), CAS-RN: 50-63-5, DTXSID7044681
|
144: Endocytic lysosomal uptake leading to liver fibrosis
|
| 390 |
Norfloxacin
|
-
Norfloxacin, CAS-RN: 70458-96-7, DTXSID7037680
|
144: Endocytic lysosomal uptake leading to liver fibrosis
|
| 514 |
Hydroquinone
|
-
Hydroquinone, CAS-RN: 123-31-9, DTXSID7020716
|
296: Oxidative DNA damage leading to chromosomal aberrations and mutations
|
| 574 |
Metyrapone
|
-
Metyrapone, CAS-RN: 54-36-4, DTXSID1023314
|
349: Inhibition of 11β-hydroxylase leading to decresed population trajectory
|
| 729 |
WIN18466
|
|
436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
|
| 728 |
4-diethylaminobenzaldehyde (DEAB)
|
|
436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
|
| 573 |
Beclomethasone dipropionate monohydrate
|
-
Beclomethasone dipropionate monohydrate, CAS-RN: 77011-63-3, DTXSID00227831
|
334: Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration
|
| 726 |
BMS-89453
|
|
436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
|
| 725 |
All-trans retinoic acid
|
|
615: Suppression of Keap1 cysteine oxidation leading to liver inflammation
|
| 723 |
Zinc
|
-
Zinc, CAS-RN: 7440-66-6, DTXSID7035012
|
615: Suppression of Keap1 cysteine oxidation leading to liver inflammation
|
| 401 |
Valproic acid
|
-
Valproic acid, CAS-RN: 99-66-1, DTXSID6023733
|
274: Histone deacetylase inhibition leads to impeded craniofacial development
|
| 402 |
Suberoylanilide hydroxamic acid
|
-
Suberoylanilide hydroxamic acid, CAS-RN: 149647-78-9, DTXSID6041133
|
274: Histone deacetylase inhibition leads to impeded craniofacial development
|
| 403 |
MS-275
|
-
MS-275, CAS-RN: 209783-80-2, DTXSID0041068
|
274: Histone deacetylase inhibition leads to impeded craniofacial development
|
| 404 |
Apicidin
|
-
Apicidin, CAS-RN: 183506-66-3, DTXSID40274182
|
274: Histone deacetylase inhibition leads to impeded craniofacial development
|
| 405 |
p,p'-DDT
|
-
DDT, CAS-RN: 50-29-3, DTXSID4020375
|
553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure
|
| 572 |
N-(5-Hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazineacetamide
|
|
348: Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory
|
| 571 |
ferric nitrilotriacetate
|
|
298: Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer
|
| 632 |
Pathogen Associated Molecular Patterns (PAMPs)
|
|
377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS)
|
| 640 |
11-Keto-testosterone
|
-
11-Ketotestosterone, CAS-RN: 564-35-2, DTXSID8036499
|
376: Androgen receptor agonism leading to male-biased sex ratio
|
| 642 |
Saracatinib
|
-
Saracatinib, CAS-RN: 379231-04-6, DTXSID90191355
|
399: Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)
|
| 641 |
Rosmarinic acid
|
|
399: Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)
|